Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have been given an average recommendation of "Buy" by the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $23.0833.
CLYM has been the subject of a number of research reports. Wedbush reiterated an "outperform" rating and issued a $20.00 price objective on shares of Climb Bio in a research note on Wednesday, August 19th. HC Wainwright raised their target price on shares of Climb Bio from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Monday. Chardan Capital started coverage on shares of Climb Bio in a report on Tuesday, May 5th. They issued a "buy" rating and a $22.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Climb Bio in a research report on Friday, July 17th. Finally, BTIG Research increased their price target on shares of Climb Bio from $19.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, June 11th.
Get Our Latest Stock Report on Climb Bio
Institutional Investors Weigh In On Climb Bio
Several hedge funds have recently made changes to their positions in CLYM. MPM Bioimpact LLC purchased a new stake in Climb Bio during the 4th quarter valued at approximately $10,686,000. BlackRock Inc. acquired a new stake in Climb Bio during the 2nd quarter worth approximately $30,708,000. Braidwell LP grew its stake in shares of Climb Bio by 102.6% in the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company's stock valued at $40,411,000 after purchasing an additional 1,569,352 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Climb Bio by 265.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company's stock valued at $7,695,000 after purchasing an additional 1,396,722 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its holdings in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company's stock valued at $5,730,000 after purchasing an additional 1,298,945 shares during the period. Institutional investors and hedge funds own 69.76% of the company's stock.
Climb Bio Stock Performance
CLYM opened at $16.40 on Tuesday. The business's 50-day simple moving average is $13.45 and its 200-day simple moving average is $10.20. Climb Bio has a one year low of $1.54 and a one year high of $18.14. The stock has a market capitalization of $942.02 million, a P/E ratio of -19.76 and a beta of 0.08.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. On average, equities research analysts forecast that Climb Bio will post -0.84 EPS for the current fiscal year.
About Climb Bio
(
Get Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
